Allogene Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $-22 |
Gross Profit | -31,164 | -3,106 | -3,099 | -3,233 |
EBITDA | -37,959 | -47,569 | -56,484 | -56,182 |
EBIT | -41,056 | -50,675 | -59,583 | -59,415 |
Net Income | -41,400 | -50,943 | -59,733 | -59,939 |
Net Change In Cash | 0 | 0 | 0 | -22 |
Free Cash Flow | -29,931 | -39,074 | -53,028 | -36,955 |
Cash | 37,815 | 52,332 | 42,455 | 75,218 |
Basic Shares | 222,038 | 218,929 | 215,359 | 210,572 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $22 | $95 | $243 | $38,489 |
Gross Profit | 22 | 95 | 243 | 38,489 |
EBITDA | -243,327 | -313,066 | -321,154 | -245,338 |
EBIT | -256,966 | -327,265 | -335,449 | -255,792 |
Net Income | -257,590 | -327,265 | -329,815 | -244,837 |
Net Change In Cash | 22 | 95 | 243 | 38,489 |
Cost of Revenue | -9,194 | |||
Free Cash Flow | -200,994 | -239,249 | -225,710 | -206,258 |
Cash | 75,218 | 83,155 | 61,904 | 173,314 |
Basic Shares | 194,812 | 156,932 | 143,147 | 135,820 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.19 |
2025-06-30 | -$0.23 |
2025-03-31 | -$0.28 |
